PROG Progenity

Progenity Announces Two Poster Presentations at Controlled Release Society 2022

Progenity Announces Two Poster Presentations at Controlled Release Society 2022

SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced the acceptance of two abstracts presenting preclinical data on its systemic therapeutics delivery system for presentation at the Controlled Release Society (CRS) 2022 Annual Meeting. CRS is an international gathering of experts in the design, development, and implementation of novel drug delivery technologies. This year’s meeting is focused on advanced delivery science and will take place in Montreal, Canada, July 11-15, 2022.

Details of the presentations are as follows:

Abstract Title:Development of ex-vivo and in-vivo models to assess the performance of an oral biotherapeutic delivery system capsule. (3732683)
Presenting Author:Christopher Wahl, MD, MBA
Session Type:Poster Session
Session Date:July 13 & 14
  
Abstract Title:Assessing the performance of an oral biotherapeutic delivery system using intra-duodenal endoscopy delivery in Yucatan minipigs (3732923)
Presenting Author:Christopher Wahl, MD, MBA
Session Type:Poster Session
Session Date:July 13 & 14

Abstracts will be published by CRS in advance of the conference. Poster presentations will be made available following the conference.

About Progenity 

Progenity, Inc. is a biotechnology company innovating in the fields of gastrointestinal health and oral biotherapeutics and is developing a suite of investigational ingestible devices designed to provide precise drug delivery solutions and diagnostic sampling. Progenity’s vision is to transform healthcare to become more precise and personal by improving patient outcomes through localized treatment with targeted therapies.

For more information visit , or follow the company on or .

Investor Contact

Chuck Padala

Managing Director, LifeSci Advisors



(917) 741-7792

Media Contact

Kristin Schaeffer

CG Life

  

(858) 457-2436



EN
06/04/2022

Underlying

PROGProgenity

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Progenity

 PRESS RELEASE
Free
PROG PROGENITY

Biora Therapeutics Successfully Completes Restructuring Process

Biora Therapeutics Successfully Completes Restructuring Process Emerges as a privately held company, with long-term financing to accelerate development of the BioJet™ platform SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Biora Therapeutics, a biotech company developing the first swallowable autoinjector, today announced the successful completion of its court-supervised restructuring. Through the restructuring process, Biora achieved an improved balance sheet with deleveraged debt and significant new financing to support the business going forward. Biora has emerged from the restructuri...

March 31, 2025 1 EN
 PRESS RELEASE
Free
PROG PROGENITY

Biora Therapeutics Undertakes Chapter 11 Sale Process to Position Busi...

Biora Therapeutics Undertakes Chapter 11 Sale Process to Position Business for Future Growth Sale process will help enable next stage of product development Secures up to $10.25 million in new financing to support ongoing business operations SAN DIEGO, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (“Biora” or the “Company”), a biotech company developing smart pill-based therapeutic platforms, today announced it has reached an agreement with certain of its prepetition creditors (the “Lenders”) to provide financing to support a chapter 11 sale process, which will ultimately l...

December 30, 2024 1 EN
 PRESS RELEASE
Free
PROG PROGENITY

Biora Therapeutics Provides Corporate Update and Reports Third Quarter...

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results Testing in advanced animal model planned in Q4 for smaller, 00-size BioJet device with largest capacity of any ingestible injectable Company granted extension until December 9 to regain compliance with Nasdaq listing requirements for market value of securities SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today provided a corporate update and reported financial results for the third quarter ended Sept...

November 14, 2024 1 EN
 PRESS RELEASE
Free
PROG PROGENITY

Biora Therapeutics to Report Third Quarter 2024 Financial Results and ...

Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the third quarter ended September 30, 2024. Company management will host a webcast and conference call on Thursday, November 14, 2024, after the close of financial markets. Conference Call and Webcast InformationDate: Thursday, November 14, 2024Time: 4:30 PM Eastern time / 1:30 PM Pacific timeCon...

November 7, 2024 1 EN
 PRESS RELEASE
Free
PROG PROGENITY

Biora Therapeutics Announces $3 Million Registered Direct Offering Pri...

Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that it has entered into definitive agreements for the purchase and sale of 745,342 shares of the Company’s common stock at an offering price of $4.025 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase ...

October 29, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch